Several Medicine by Design-funded investigators were named Canada Research Chairs, and two received New Frontiers in Research Fund (NFRF) Transformation stream grants.
Projects to impact autoimmune, intestinal and degenerative eye diseases
Research shows that transplanted pancreatic cells were able to survive in animal hosts.
"Our lab’s work is a good example of why it’s an exciting time to be in regenerative medicine: tissue engineering and regenerative medicine strategies enable us to model a disease in the lab, which can help us answer big unknowns."
Themes like lessons learned from COVID-19, symbiotic partnerships and access to risk capital emerge in wide-ranging discussion.
Is immunoengineering the key to ensuring that cell therapies can treat disease?
The 6th Annual Symposium on Dec. 9 and 10 will feature renowned experts to explore cutting-edge concepts in health research and innovation.
Cells transplanted into the retina transfer materials to recipient cells through nanotubes.
Newly-generated cells may lead to a deeper understanding of bile duct disease and be a powerful tool for finding new treatments.
“I hope my impact on science is two-fold. It's enjoyable to mentor young scientists who are developing their scientific thinking and their love of discovery. I also hope my research one day translates into something that helps patients."
Entrepreneur-in-residence to work on bridging the gap between foundational research funded by Medicine by Design and the creation of products or ventures that will impact human health.
“Science is about interpreting hard numbers and data, but I’ve realized that science is also an exercise in creative storytelling. I love the visual arts and literature, and I can see the drama in science."
The program’s second year includes new partnerships, enhanced educational opportunities and more research funding.
Scientists at the University of Toronto have discovered a novel way to test self-repair of skeletal muscle, a method with the potential to accelerate treatments for diseases like muscular dystrophy.
Can turning off genetic switches in therapeutic cells help them avoid attack from the immune system?
